Abstract
Although adaptive cancer therapy shows promise in integrating evolutionary dynamics into treatment scheduling, the stochastic nature of cancer evolution has seldom been taken into account. Various sources of random perturbations can impact the evolution of heterogeneous tumors, making performance metrics of any treatment policy random as well. In this paper, we propose an efficient method for selecting optimal adaptive treatment policies under randomly evolving tumor dynamics. The goal is to improve the cumulative “cost” of treatment, a combination of the total amount of drugs used and the total treatment time. As this cost also becomes random in any stochastic setting, we maximize the probability of reaching the treatment goals (tumor stabilization or eradication) without exceeding a pre-specified cost threshold (or a “budget”). We use a novel Stochastic Optimal Control formulation and Dynamic Programming to find such “threshold-aware” optimal treatment policies. Our approach enables an efficient algorithm to compute these policies for a range of threshold values simultaneously. Compared to treatment plans shown to be optimal in a deterministic setting, the new “threshold-aware” policies significantly improve the chances of the therapy succeeding under the budget, which is correlated with a lower general drug usage. We illustrate this method using two specific examples, but our approach is far more general and provides a new tool for optimizing adaptive therapies based on a broad range of stochastic cancer models.
Funder
Division of Mathematical Sciences
Division of Cancer Epidemiology and Genetics, National Cancer Institute
American Cancer Society
Publisher
Public Library of Science (PLoS)
Reference66 articles.
1. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy;RB Martin;Mathematical Biosciences,1992
2. Optimization of an in vitro chemotherapy to avoid resistant tumours;C Carrère;Journal of Theoretical Biology,2017
3. Stability and reachability analysis for a controlled heterogeneous population of cells;C Carrère;Optimal Control Applications and Methods,2020
4. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy;RS Day;Cancer Research,1986